Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this article, data from two cohorts of patients with pancreatic and biliary cancers with CDKN2A loss or mutation treated with palbociclib are reported.Eligible patients age 12 years and older with advanced...